Trial-in-progress abstract highlights new cohort that could expand the company's pancreatic cancer programPelareorep's ability to expand TILs highlights its immunotherapeutic mechanism of action and potential as a backbone immunotherapy for multiple indicationsSAN DIEGO and CALGARY, AB, May 24, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, presented two abstracts at the 2024 American Society of Clinical O ...

USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, May 23, 2024 /PRNewswire/ -- USA News Group – Known as one of the deadliest cancers, researchers are working diligently to help increase the chance of survival for pancreatic cancer patients through earlier detection, as according to Johns Hopkins Medicine up to 80% of patients, are diagnosed at later, more difficult-to-treat stages. Now, researchers have identified specific circulating microRNAs (miRNAs) in blood samples t ...

USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, May 17, 2024 /PRNewswire/ -- USA News Group – A new study is bringing hope in the fight against one of the deadliest cancers, revealing a blood test that can detect early-stage pancreatic cancer with 97% accuracy. This breakthrough is crucial, as Johns Hopkins Medicine reports that up to 10% of patients diagnosed early can become disease-free after treatment. The American Cancer Society estimates that around 66,440 people ( ...

SAN DIEGO and CALGARY, AB, May 16, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Wednesday, May 15, 2024. A total of 41.34% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting. On a vote by ballot, the eight nominees proposed by the Corpor ...

USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, May 15, 2024 /PRNewswire/ -- USA News Group – Hope is rising in the fight against one of the deadliest cancers in the world, as a new study recently claimed that a blood test can accurately detect early-stage pancreatic cancer with 97% accuracy. According to Johns Hopkins Medicine, up to 10% of patients who receive an early diagnosis become disease-free after treatment, meaning the earlier it's detected, the better the pati ...

财务数据和关键指标变化 - 公司2024年第一季度现金及现金等价物为2960万加元,较2023年12月31日的3490万加元减少[48] - 2024年第一季度净亏损690万加元,较2023年同期的640万加元增加[50] - 2024年第一季度一般及行政费用为300万加元,较2023年同期的320万加元减少[51] - 2024年第一季度研发费用为570万加元,较2023年同期的350万加元增加,主要由于完成CGMP生产批次及相关检测的制造费用增加[52] 各条业务线数据和关键指标变化 - 公司正在推进pelareorep在乳腺癌和胰腺癌两大适应症的注册临床试验[12][29][30][31][32][33][34][35][45] - 公司正在扩大GOBLET研究中肛门癌队列的入组,以确认之前观察到的疗效信号,为加速注册提供依据[40][41] - 公司新增GOBLET研究中一个胰腺癌队列,评估pelareorep联合改良FOLFIRINOX化疗,加或不加atezolizumab[42][43][44] 各个市场数据和关键指标变化 - 无相关内容 公司战略和发展方向及行业竞争 - 公司正在向后期肿瘤公司转型,推进pelareorep在乳腺癌和胰腺癌的注册临床试验[12][20][27][55][57] - pelareorep作为一种差异化的免疫治疗药物,在多项临床试验中显示出与化疗、免疫检查点抑制剂等联合使用的协同疗效[16][17][18][19] - 公司正在与临床合作者和潜在战略合作伙伴保持积极沟通,以丰富注册试验方案[26][57] 管理层对经营环境和未来前景的评论 - 公司对pelareorep作为一种有潜力的肿瘤免疫治疗药物表示乐观[12][16][17][18][19][55][57] - 公司认为pelareorep在乳腺癌和胰腺癌两大适应症取得注册批准是关键目标[12][27][55] - 公司认为GOBLET研究中肛门癌队列的扩充可能为pelareorep开辟新的注册适应症[21][40][41] 问答环节重要的提问和回答 问题1 **John Newman 提问** 询问公司在转移性乳腺癌适应症的注册临床试验设计[60] **Thomas Heineman 回答** 公司计划与FDA讨论最合适的注册试验设计,包括目标人群、主要终点等关键要素,以期设计出高效灵活、时间线短且有望直接获批的试验[62][63] 问题2 **Unidentified Analyst 提问** 询问公司在胰腺癌适应症两个临床试验的关系和注册策略[65] **Matthew Coffey 回答** 公司计划同时评估pelareorep联合两种常用化疗方案(gem/nab-paclitaxel和mFOLFIRINOX)在一线胰腺癌患者中的疗效,以覆盖尽可能广泛的患者群体[67][68][69][70][71] 问题3 **Unidentified Analyst 提问** 询问公司即将在ASCO会议上展示的mFOLFIRINOX联合试验数据[76] **Matthew Coffey 回答** 公司在ASCO会议上将展示一个试验进展的海报,介绍该项正在招募患者的临床试验的设计,但不会有任何数据结果[77]

Condensed Interim Consolidated Financial Statements (unaudited) Oncolytics Biotech Inc. For the three months ended March 31, 2024 ® | --- | --- | --- | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------------|-------|------------------|-------|---------------------| | As at \nAssets | | March 31, 2024 | | December 31, 2023 | | Current assets | | | | | | Cash and cash equivalents (note 4) | $ | 29,603 | $ | 34,912 ...

FN Media Group News Commentary PALM BEACH, Fla., May 9, 2024 /PRNewswire/ -- The incidence of pancreatic cancer is increasing globally, which is driving the growth of the market. As of 2023, the American Cancer Society predicts that 64,050 Americans will be diagnosed with pancreatic cancer. It is estimated that 50,550 people will die from pancreatic cancer (26,620 men and 23,930 women). Pancreatic cancer is an aggressive form of cancer, and it is often not detected until it is in an advanced stage. Additio ...

USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, May 9, 2024 /PRNewswire/ -- USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's "Cancer Moon Shot" designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around ...

US$5 million PanCAN grant provides important support for the fifth cohort of the GOBLET study Study of modified FOLFIRINOX/pelareorep/atezolizumab (Tecentriq®) combination expands existing pancreatic cancer program First patient expected to be enrolled in Q2 2024 SAN DIEGO and CALGARY, AB, May 9, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, will commence enrollment into a new GOBLET study pancreatic canc ...